NNNN Company Details

About Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.

Exchange

NASDAQ

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Employees

27

Price

$6.05

Previous close

$6.06

Market capitalization

$265.98M

Volume

636,314

P/E ratio

31.33

52-week low

$5.13

52-week high

$51.33

Additional performance and financial-statement views load in the interactive application.